Share on StockTwits

Research analysts at Wedbush raised their target price on shares of Sequenom (NASDAQ:SQNM) to $5.00 in a report released on Tuesday. Wedbush’s price target points to a potential upside of 49.70% from the company’s current price.

Separately, analysts at ISI Group reiterated a “buy” rating on shares of Sequenom in a research note on Monday, June 2nd. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Sequenom presently has a consensus rating of “Hold” and a consensus price target of $6.33.

Shares of Sequenom (NASDAQ:SQNM) traded up 3.59% during mid-day trading on Tuesday, hitting $3.4599. 1,444,759 shares of the company’s stock traded hands. Sequenom has a one year low of $1.65 and a one year high of $4.90. The stock has a 50-day moving average of $2.88 and a 200-day moving average of $2.52. The company’s market cap is $402.7 million.

Sequenom (NASDAQ:SQNM) last announced its earnings results on Thursday, May 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. The company had revenue of $46.30 million for the quarter, compared to the consensus estimate of $46.06 million. During the same quarter in the previous year, the company posted ($0.26) earnings per share. The company’s revenue for the quarter was up 20.3% on a year-over-year basis. On average, analysts predict that Sequenom will post $-0.35 earnings per share for the current fiscal year.

Manufactures DNA detection and sequencing equipment. The Company’s two business units combine to utilize their MassARRAY system, SNP assay portfolio, disease gene discovery programs and DNA sample repository.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.